{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["van den Berg SA"],"funding":["Medtronic","Health~Holland","Top Sector Life Sciences & Health","Top Sector Life Sciences &amp; Health","Hartstichting","Hersenstichting"],"pagination":["383"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6595565"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Some studies have suggested that transdermal administration of glyceryl trinitrate (GTN; nitroglycerin) in the first few hours after symptom onset increases the chance of a favourable outcome after ischaemic stroke or intracerebral haemorrhage, possibly through an increase in intracranial collateral blood flow and a reduction in blood pressure. The Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP) aims to assess the effect of transdermal GTN, started within 3 h after stroke onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage.<h4>Methods</h4>MR ASAP is a phase III, multicentre, randomised, open-label clinical trial with a blinded o"],"journal":["Trials"],"pubmed_title":["Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP): study protocol for a randomised controlled trial."],"pmcid":["PMC6595565"],"funding_grant_id":["HA2015.01.06","LSHM17016","CVON2015-01: CONTRAST"],"pubmed_authors":["Nederkoorn PJ","van den Berg SA","Fransen PSS","van der Worp HB","MR ASAP Investigators","Siegers A","Hofmeijer J","Caminada K","Kerkhoff H","de Leeuw FE","Kruyt ND","Dippel DWJ"],"additional_accession":[]},"is_claimable":false,"name":"Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP): study protocol for a randomised controlled trial.","description":"<h4>Background</h4>Some studies have suggested that transdermal administration of glyceryl trinitrate (GTN; nitroglycerin) in the first few hours after symptom onset increases the chance of a favourable outcome after ischaemic stroke or intracerebral haemorrhage, possibly through an increase in intracranial collateral blood flow and a reduction in blood pressure. The Multicentre Randomised trial of Acute Stroke treatment in the Ambulance with a nitroglycerin Patch (MR ASAP) aims to assess the effect of transdermal GTN, started within 3 h after stroke onset in the prehospital setting, on functional outcome at 90 days in patients with acute ischaemic stroke or intracerebral haemorrhage.<h4>Methods</h4>MR ASAP is a phase III, multicentre, randomised, open-label clinical trial with a blinded o","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Jun","modification":"2026-05-05T01:15:52.992Z","creation":"2019-08-12T07:02:13Z"},"accession":"S-EPMC6595565","cross_references":{"pubmed":["31242931"],"doi":["10.1186/s13063-019-3419-z"]}}